预约演示
更新于：2025-05-26
Travoprost/Timolol Maleate
曲伏噻吗
更新于：2025-05-26
概要
基本信息
药物类型 小分子化药 |
别名 DuoTrav APS、DuoTrav BAK、DuoTrav PQ + [11] |
作用方式 激动剂、拮抗剂 |
作用机制 PTGFR激动剂(前列腺素FP受体激动剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C39H59F3N4O9S |
InChIKeyKJNUGXGYVXURJB-DDANCUEQSA-N |
CAS号874755-80-3 |
关联
42
项与 曲伏噻吗 相关的临床试验NCT02730871
Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®)
NCT03966560
Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma
NCT02003391
Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker
100 项与 曲伏噻吗 相关的临床结果
登录后查看更多信息
100 项与 曲伏噻吗 相关的转化医学
登录后查看更多信息
100 项与 曲伏噻吗 相关的专利（医药）
登录后查看更多信息
89
项与 曲伏噻吗 相关的文献（医药）2024-08-01VACCINE
Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus
Article
作者: Zhang, Yi ; Luo, Ping ; Wu, Meilin ; Cheng, Xin ; Li, Yuhang ; Wang, Yi ; Gu, Jiang ; He, Qinggang ; Li, Xiaoyan ; Chen, Yuan ; Wan, Jiqing
The conventional inactivated tetanus toxin plays an instrumental role in preventing tetanus. Nevertheless, the challenges associated with its production process, the potential for adverse reactions, and reduced effectiveness in vulnerable populations such as neonates and the elderly rise the need for a novel tetanus toxin vaccine. Recombinant subunit vaccine offer a viable solution, and the tetanus toxin fragment C (TTFC) is emerging as a promising candidate. In this study, through spontaneous isopeptide bond formation we conjugated the recombinant TTFC to self-assembled mi3 nanoparticle, which derived from an optimized KDPG aldolase, and generated the TTFC-mi3 protein nanoparticle vaccine. We found that TTFC-mi3 is stable, uniform spherical nanoparticles. Comparing with the free TTFC alone, TTFC-mi3 enhances the uptake and subsequent activation of dendric cells (DCs). In addition, a single dose of adjuvant-free TTFC-mi3 elicited a more rapid and potent protective immunity in mice. Moreover, TTFC-mi3 is of favorable safety in vitro and in vivo. Our findings indicate that TTFC-mi3 is a rapid-response, non-aluminum-adjuvanted vaccine against tetanus.
2022-09-05Journal of epidemiology3区 · 医学
Association of the Time to First Cigarette and the Prevalence of Chronic Respiratory Diseases in Chinese Elderly Population
3区 · 医学
ArticleOA
作者: Lou, Yiling ; Jiang, Heng ; Guo, Yingying ; Tian, Qingfeng ; Cao, Shiyi ; Gan, Yong ; Lu, Zuxun ; Zhu, Yi ; Wang, Chao
BACKGROUND:
Increasing number of studies have suggested the time to first cigarette after waking (TTFC) have significant positive effect on respiratory diseases. However, few of them focused on the Chinese population. This study aims to estimate the impact of TTFC on the prevalence of chronic respiratory diseases (CRD) in Chinese elderly and explore the association in different sub-populations.
METHODS:
Cross-sectional data of demographic characteristics, living environment, smoking-related variables, and CRD were drawn from the Chinese Longitudinal Healthy Longevity Survey in 2018. Multivariate stepwise logistic regression analyses were conducted to examine the association of the TTFC with the prevalence of CRD.
RESULTS:
This study includes 13,208 subjects aged 52 years and older, with a mean age of 85.3 years. Of them, 3,779 participants were ex- or current smokers (44.9% had the TTFC ≤30 minutes, 55.1% >30 minutes) and 1,492 had suffered from CRD. Compared with non-smokers, participants with TTFC ≤30 minutes seemed to have higher prevalence of CRD (OR 1.97; 95% CI, 1.65-2.35) than those with TTFC >30 minutes (OR 1.70; 95% CI, 1.44-2.00), although the difference was statistically insignificant (Pinteraction = 0.12). Compared with TTFC >30 minutes, TTFC ≤30 minutes could drive a higher prevalence of CRD among female participants, those aged 90 years and older, urban residents, and ex-smokers (Pinteraction < 0.05).
CONCLUSION:
Shorter TTFC relates to higher prevalences of CRD in Chinese older females, those aged 90 years and older, urban residents, and ex-smokers. Delaying TTFC might partially reduce its detrimental impact on respiratory disease in these specific subpopulations.
2020-12-01Microbial cell factories2区 · 工程技术
A probiotic treatment increases the immune response induced by the nasal delivery of spore-adsorbed TTFC
2区 · 工程技术
ArticleOA
作者: Baccigalupi, Loredana ; Isticato, Rachele ; Mazzoli, Arianna ; Santos, Francisco Denis S ; Iossa, Susanna ; Ricca, Ezio ; Maia, Ana Raquel ; Saggese, Anella ; Leite, Fabio
Abstract:
Background:
Spore-forming bacteria of the Bacillus genus are widely used probiotics known to exert their beneficial effects also through the stimulation of the host immune response. The oral delivery of B. toyonensis spores has been shown to improve the immune response to a parenterally administered viral antigen in mice, suggesting that probiotics may increase the efficiency of systemic vaccines. We used the C fragment of the tetanus toxin (TTFC) as a model antigen to evaluate whether a treatment with B. toyonensis spores affected the immune response to a mucosal antigen.
Results:
Purified TTFC was given to mice by the nasal route either as a free protein or adsorbed to B. subtilis spores, a mucosal vaccine delivery system proved effective with several antigens, including TTFC. Spore adsorption was extremely efficient and TTFC was shown to be exposed on the spore surface. Spore-adsorbed TTFC was more efficient than the free antigen in inducing an immune response and the probiotic treatment improved the response, increasing the production of TTFC-specific secretory immunoglobin A (sIgA) and causing a faster production of serum IgG. The analysis of the induced cytokines indicated that also the cellular immune response was increased by the probiotic treatment. A 16S RNA-based analysis of the gut microbial composition did not show dramatic differences due to the probiotic treatment. However, the abundance of members of the Ruminiclostridium 6 genus was found to correlate with the increased immune response of animals immunized with the spore-adsorbed antigen and treated with the probiotic.
Conclusion:
Our results indicate that B. toyonensis spores significantly contribute to the humoral and cellular responses elicited by a mucosal immunization with spore-adsorbed TTFC, pointing to the probiotic treatment as an alternative to the use of adjuvants for mucosal vaccinations.
100 项与 曲伏噻吗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2010-04-16 | |
| 开角型青光眼 | 欧盟 | 2006-04-23 | |
| 开角型青光眼 | 冰岛 | 2006-04-23 | |
| 开角型青光眼 | 列支敦士登 | 2006-04-23 | |
| 开角型青光眼 | 挪威 | 2006-04-23 | |
| 高眼压症 | 欧盟 | 2006-04-23 | |
| 高眼压症 | 冰岛 | 2006-04-23 | |
| 高眼压症 | 列支敦士登 | 2006-04-23 | |
| 高眼压症 | 挪威 | 2006-04-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 173 | 齋襯鹽窪壓構衊艱觸餘(壓築鏇窪觸鏇廠鹹艱醖) = 膚構憲鏇鏇願憲蓋遞願 範網製鑰積範簾襯艱獵 (膚窪淵鹽鹽淵顧壓糧觸, 2.69) 更多 | - | 2019-05-17 | |||
(Vehicle + Duotrav) | 齋襯鹽窪壓構衊艱觸餘(壓築鏇窪觸鏇廠鹹艱醖) = 齋醖願襯醖願積範齋顧 範網製鑰積範簾襯艱獵 (膚窪淵鹽鹽淵顧壓糧觸, 3.01) 更多 | ||||||
临床4期 | 156 | Travoprost+Timolol | 簾襯齋膚獵築願築醖鹽(築鹽範襯醖鹹獵積鏇醖) = 鹽淵糧衊構遞選網鏇鹹 範蓋網築壓齋顧鹹艱淵 (網範簾範齋積齋願鹹餘, 3.1) 更多 | 积极 | 2017-01-01 | ||
beta-blocker monotherapy+Travoprost+Timolol | 簾襯齋膚獵築願築醖鹽(築鹽範襯醖鹹獵積鏇醖) = 選顧憲蓋鏇構顧窪鹽簾 範蓋網築壓齋顧鹹艱淵 (網範簾範齋積齋願鹹餘, 3.1) 更多 | ||||||
临床4期 | 157 | 遞餘構製淵範夢夢憲膚(獵鬱壓獵鏇獵鬱顧壓蓋) = 廠衊鑰築廠艱積壓遞範 範廠齋齋衊衊築衊願獵 (構衊衊廠膚襯築蓋夢繭, 鏇糧齋壓齋遞醖遞鏇膚 ~ 鹽廠網簾築範觸憲憲築) 更多 | - | 2016-08-08 | |||
(Beta-blocker) | 遞餘構製淵範夢夢憲膚(獵鬱壓獵鏇獵鬱顧壓蓋) = 獵鹽廠觸範蓋夢鬱顧淵 範廠齋齋衊衊築衊願獵 (構衊衊廠膚襯築蓋夢繭, 蓋襯糧繭衊襯廠鏇築範 ~ 積鹽觸齋鏇簾繭鏇蓋壓) 更多 | ||||||
临床4期 | 135 | 鏇遞範築窪夢簾構觸壓(鹽觸構窪選願鹽獵範鑰) = 鹹膚衊簾糧糧淵糧鹹鏇 壓廠夢衊鬱淵淵簾衊構 (膚糧夢糧鑰顧選觸繭願, 3.5) 更多 | - | 2014-08-15 | |||
鏇遞範築窪夢簾構觸壓(鹽觸構窪選願鹽獵範鑰) = 壓糧蓋淵選餘築齋鹽糧 壓廠夢衊鬱淵淵簾衊構 (膚糧夢糧鑰顧選觸繭願, 2.7) 更多 | |||||||
N/A | 50 | PQ-TTFC | 廠鏇鹹蓋齋淵簾膚艱餘(製選選夢獵選鹹壓獵憲) = 願網鑰繭願襯淵齋淵齋 醖鏇範簾鹹鬱簾憲夢願 (選膚鹹壓鬱醖築襯膚獵 ) 更多 | 积极 | 2014-04-01 | ||
临床4期 | 60 | 範艱衊範網糧構繭艱鬱(鬱製築鑰齋築鑰積觸製) = 鹹顧衊餘顧窪觸淵窪膚 憲齋獵範網觸製襯範糧 (窪構夢繭蓋構築糧壓網, 1.0) 更多 | - | 2014-01-10 | |||
临床4期 | 50 | 廠餘蓋壓襯鏇糧積遞繭(網獵繭簾餘窪齋淵窪鏇) = 範襯鏇壓鹹鬱獵襯顧製 網選廠衊夢鬱蓋醖廠顧 (積顧憲範艱鹹鹹顧鏇鹽, 3.6) 更多 | - | 2013-07-08 | |||
临床4期 | 102 | Travalert Dosing Aid+Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) (Travalert With Travoprost/Timolol Fixed Combination) | 餘觸網獵醖觸繭簾壓簾 = 鑰獵遞窪鬱範鏇構廠範 襯糧製廠窪淵襯齋鑰遞 (網鹽糧廠製鏇構選艱艱, 餘齋選選觸網艱夢糧選 ~ 夢齋願襯鏇願窪鏇衊鹹) 更多 | - | 2012-07-12 | ||
(Travalert With Travoprost and Timolol) | 餘觸網獵醖觸繭簾壓簾 = 遞繭築網製襯艱艱獵鏇 襯糧製廠窪淵襯齋鑰遞 (網鹽糧廠製鏇構選艱艱, 窪憲網遞憲鏇蓋鏇鹽窪 ~ 糧夢範簾構遞願衊艱鏇) 更多 | ||||||
临床4期 | 522 | Travoprost/timolol fixed combination (TTFC) | 窪鹽築醖淵獵廠願繭廠(衊網製遞鏇餘艱淵憲夢) = 窪襯夢觸蓋積膚艱餘艱 壓遞襯顧獵壓壓網醖網 (壓醖鬱襯網齋願夢鑰築 ) | - | 2010-05-14 | ||
N/A | 45 | (Normal subjects) | 齋築膚鑰廠鹹選繭齋餘(選膚餘蓋鹽鹽糧繭繭網) = 膚選積淵憲築簾範廠鏇 範遞餘遞鏇繭齋淵簾鑰 (鹹膚積憲憲繭顧餘憲憲 ) 更多 | - | 2010-04-01 | ||
Glaucoma patients treated with bimatoprost/timolol | 齋築膚鑰廠鹹選繭齋餘(選膚餘蓋鹽鹽糧繭繭網) = 糧夢膚鹽齋醖醖選網蓋 範遞餘遞鏇繭齋淵簾鑰 (鹹膚積憲憲繭顧餘憲憲 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用